 CHICAGO--BUSINESS WIRE-- GvokeHypoPen--Xeris Biopharma Holdings, Inc. Nasdaq: XERS, a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced topline results from its Phase 1 study of subcutaneous SC levothyroxine XP-8121 in healthy adult volunteers. 